The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Anti‐tumour strategies aiming to target tumour‐associated macrophages
Open accessAbstract
Summary: Tumour‐associated macrophages (TAM s) represent a predominant population of inflammatory cells that present in solid tumours. TAM s are mostly characterized as alternatively activated M2‐like macrophages and are known to orchestrate nearly all stages of tumour progression. Experimental investigations indicate that TAM s contribute to drug‐resistance and radio‐protective effects, and clinical evidence shows that an elevated number of TAM s and their M2 profile are correlated with therapy failure and poor prognosis in cancer patients. Recently, many studies on TAM‐targeted strategies have made significant progress and some pilot works have achieved encouraging results. Among these, connections between some anti‐tumour drugs and their influence on TAM s have been suggested. In this review, we will summarize recent advances in TAM‐targeted strategies for tumour therapy. Based on the proposed mechanisms, those strategies are grouped into four categories: (i) inhibiting macrophage recruitment; (ii) suppressing TAM survival; (iii) enhancing M1‐like tumoricidal activity of TAM s; (iv) blocking M2‐like tumour‐promoting activity of TAM s. It is desired that further attention be drawn to this research field and more effort be made to promote TAM‐targeted tumour therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chatterjee, S., Mookerjee, A., Basu, J. M., Chakraborty, P., Ganguly, A., Adhikary, A., Mukhopadhyay, D., Ganguli, S., Banerjee, R., Ashraf, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007048 · Cited by 46
RetractedA Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α
Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., Johnson, R. S., Haddad, G. G., & Karin, M. (2008) · Nature · doi:10.1038/nature06905 · Cited by 1,614
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
Solinas, G., Germano, G., Mantovani, A., & Allavena, P. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0609385 · Cited by 1,425
Bouhlel, M. A., Derudas, B., Rigamonti, E., Dièvart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.06.010 · Cited by 1,325
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Macrophage polarization in tumour progression
Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M., Biswas, S. K., Allavena, P., & Mantovani, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.004 · Cited by 1,241
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H., VandenBerg, S., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,130
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
Kim, S., Takahashi, H., Lin, W.-W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.-L., & Karin, M. (2009) · Nature · doi:10.1038/nature07623 · Cited by 1,100
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.
Allavena, P., Sica, A., Solinas, G., Porta, C., & Mantovani, A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.07.004 · Cited by 1,044
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Targeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
The diverse and complex roles of NF-κB subunits in cancer
Perkins, N. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3204 · Cited by 852
“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
Krüppel-like factor 4 regulates macrophage polarization
Liao, X., Sharma, N., Kapadia, F., Zhou, G., Lu, Y., Hong, H., Paruchuri, K., Mahabeleshwar, G. H., Dalmas, E., Venteclef, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45444 · Cited by 778
Giraudo, E., Inoue, M., & Hanahan, D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422087 · Cited by 700
Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695
Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W., & Johnson, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1439 · Cited by 652
CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3
Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Chen, J., Liu, B., Deng, H., Wang, F., Lin, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.006 · Cited by 641
Zeisberger, S. M., Odermatt, B., Marty, C., Zehnder-Fjällman, A. H. M., Ballmer-Hofer, K., & Schwendener, R. A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603240 · Cited by 623
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
The inflammatory chemokines CCL2 and CCL5 in breast cancer
Soria, G., & Ben-Baruch, A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.018 · Cited by 593
Roca, H., Varsos, Z. S., Sud, S., Craig, M. J., Ying, C., & Pienta, K. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042671 · Cited by 569
Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
Zhu, X.-D., Zhang, J.-B., Zhuang, P.-Y., Zhu, H.-G., Zhang, W., Xiong, Y.-Q., Wu, W.-Z., Wang, L., Tang, Z.-Y., & Sun, H.-C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6521 · Cited by 556
Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer
Kurahara, H., Shinchi, H., Mataki, Y., Maemura, K., Noma, H., Kubo, F., Sakoda, M., Ueno, S., Natsugoe, S., & Takao, S. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2009.05.026 · Cited by 552
Targeting tumor-associated macrophages as a novel strategy against breast cancer
Luo, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27648 · Cited by 552
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Suzuki, T., Franchi, L., Toma, C., Ashida, H., Ogawa, M., Yoshikawa, Y., Mimuro, H., Inohara, N., Sasakawa, C., & Nuñez, G. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030111 · Cited by 535
Xin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4323 · Cited by 504
Sinha, P., Clements, V. K., & Ostrand-Rosenberg, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.636 · Cited by 466
Imtiyaz, H. Z., Williams, E. P., Hickey, M. M., Patel, S. A., Durham, A. C., Yuan, L.-J., Hammond, R., Gimotty, P. A., Keith, B., & Simon, M. C. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39506 · Cited by 461
Farinha, P., Masoudi, H., Skinnider, B. F., Shumansky, K., Spinelli, J. J., Gill, K., Klasa, R., Voss, N., Connors, J. M., & Gascoyne, R. D. (2005) · Blood · doi:10.1182/blood-2005-04-1565 · Cited by 461
Ma, J., Liu, L., Che, G., Yu, N., Dai, F., & You, Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-112 · Cited by 437
Biswas, S. K., Sica, A., & Lewis, C. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2011 · Cited by 435
Macrophage Responses to Hypoxia
Lewis, C., & Murdoch, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62038-x · Cited by 413
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D. A., Thompson, R., Schioppa, T., Nemeth, J., Vermeulen, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0945 · Cited by 390
Puig-Kröger, A., Sierra-Filardi, E., Domínguez-Soto, A., Samaniego, R., Corcuera, M. T., Gómez-Aguado, F., Ratnam, M., Sánchez-Mateos, P., & Corbí, A. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2050 · Cited by 389
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
Krieg, A. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210911 · Cited by 388
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis
Kubota, Y., Takubo, K., Shimizu, T., Ohno, H., Kishi, K., Shibuya, M., Saya, H., & Suda, T. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081605 · Cited by 388
Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology
Pello, O. M., De Pizzol, M., Mirolo, M., Soucek, L., Zammataro, L., Amabile, A., Doni, A., Nebuloni, M., Swigart, L. B., Evan, G. I., et al. (2012) · Blood · doi:10.1182/blood-2011-02-339911 · Cited by 386
A Critical Role for Stat3 Signaling in Immune Tolerance
Cheng, F., Wang, H.-W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00232-2 · Cited by 377
Zhang, W., Zhu, X.-D., Sun, H.-C., Xiong, Y.-Q., Zhuang, P.-Y., Xu, H.-X., Kong, L.-Q., Wang, L., Wu, W.-Z., & Tang, Z.-Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2904 · Cited by 374
Welsh, T. J., Green, R. H., Richardson, D., Waller, D. A., O'Byrne, K. J., & Bradding, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4910 · Cited by 369
Ahn, G.-O., Tseng, D., Liao, C.-H., Dorie, M. J., Czechowicz, A., & Brown, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911378107 · Cited by 347
Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
Song, L., Asgharzadeh, S., Salo, J., Engell, K., Wu, H.-W., Sposto, R., Ara, T., Silverman, A. M., DeClerck, Y. A., Seeger, R. C., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37869 · Cited by 342
Liu, C., Sun, C., Huang, H., Janda, K. D., & Edgington, T. S. (2003) · PubMed · Cited by 334
Duluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E., Ponsoda, S., Delneste, Y., Hebbar, M., & Jeannin, P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24401 · Cited by 329
Tumour macrophages as potential targets of bisphosphonates
Rogers, T. L., & Holen, I. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-177 · Cited by 324
Fang, H.-Y., Hughes, R., Murdoch, C., Coffelt, S. B., Biswas, S. K., Harris, A. L., Johnson, R. S., Imityaz, H. Z., Simon, M. C., Fredlund, E., et al. (2009) · Blood · doi:10.1182/blood-2008-12-195941 · Cited by 319
Hussain, S. F., Kong, L.-Y., Jordan, J., Conrad, C., Madden, T., Fokt, I., Priebe, W., & Heimberger, A. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1243 · Cited by 314
Gazzaniga, S., Bravo, A. I., Guglielmotti, A., van Rooijen, N., Maschi, F., Vecchi, A., Mantovani, A., Mordoh, J., & Wainstok, R. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700827 · Cited by 302
MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles
Daldrup-Link, H. E., Golovko, D., Ruffell, B., DeNardo, D. G., Castaneda, R., Ansari, C., Rao, J., Tikhomirov, G. A., Wendland, M. F., Corot, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3420 · Cited by 300
TLR7 and TLR8 as targets in cancer therapy
Schön, M. P., & Schön, M. (2008) · Oncogene · doi:10.1038/sj.onc.1210913 · Cited by 296
Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., Olimpio, C. O., Bonardi, C., Garbi, A., Lissoni, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4037 · Cited by 286
Prognostic value of tumor‐associated macrophage count in human bladder cancer
Hanada, T., Nakagawa, M., Emoto, A., Nomura, T., Nasu, N., & Nomura, Y. (2000) · International Journal of Urology · doi:10.1046/j.1442-2042.2000.00190.x · Cited by 283
Eidtmann, H., de Boer, R., Bundred, N., Llombart-Cussac, A., Davidson, N., Neven, P., von Minckwitz, G., Miller, J., Schenk, N., & Coleman, R. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq217 · Cited by 281
Coscia, M., Quaglino, E., Iezzi, M., Curcio, C., Pantaleoni, F., Riganti, C., Holen, I., Mönkkönen, H., Boccadoro, M., Forni, G., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00926.x · Cited by 275
Watkins, S. K., Egilmez, N. K., Suttles, J., & Stout, R. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1357 · Cited by 273
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Germano, G., Frapolli, R., Simone, M., Tavecchio, M., Erba, E., Pesce, S., Pasqualini, F., Grosso, F., Sanfilippo, R., Casali, P. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2335 · Cited by 267
Clark, R. A., Huang, S. J., Murphy, G. F., Mollet, I. G., Hijnen, D., Muthukuru, M., Schanbacher, C. F., Edwards, V., Miller, D. M., Kim, J. E., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071190 · Cited by 243
Paulus, P., Stanley, E. R., Schäfer, R., Abraham, D., & Aharinejad, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3523 · Cited by 231
Welford, A. F., Biziato, D., Coffelt, S. B., Nucera, S., Fisher, M., Pucci, F., Di Serio, C., Naldini, L., De Palma, M., Tozer, G. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44562 · Cited by 228
Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors
Shime, H., Matsumoto, M., Oshiumi, H., Tanaka, S., Nakane, A., Iwakura, Y., Tahara, H., Inoue, N., & Seya, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113099109 · Cited by 224
Mizutani, K., Sud, S., McGregor, N. A., Martinovski, G., Rice, B. T., Craig, M. J., Varsos, Z. S., Roca, H., & Pienta, K. J. (2009) · Neoplasia · doi:10.1593/neo.09988 · Cited by 220
Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth
Zhang, J., Lu, Y., & Pienta, K. J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq044 · Cited by 216
Cancer‐promoting tumor‐associated macrophages: New vistas and open questions
Mantovani, A., Germano, G., Marchesi, F., Locatelli, M., & Biswas, S. K. (2011) · European Journal of Immunology · doi:10.1002/eji.201141894 · Cited by 207
Carpentier, A., Metellus, P., Ursu, R., Zohar, S., Lafitte, F., Barrie, M., Meng, Y., Richard, M., Parizot, C., Laigle-Donadey, F., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop047 · Cited by 206
Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results
Cluff, C. W. (2009) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-1603-7_10 · Cited by 205
Dineen, S. P., Lynn, K. D., Holloway, S. E., Miller, A. F., Sullivan, J. P., Shames, D. S., Beck, A. W., Barnett, C. C., Fleming, J. B., & Brekken, R. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6705 · Cited by 203
Blockade of a Chemokine, CCL2, Reduces Chronic Colitis-Associated Carcinogenesis in Mice
Popivanova, B. K., Kostadinova, F. I., Furuichi, K., Shamekh, M. M., Kondo, T., Wada, T., Egashira, K., & Mukaida, N. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1451 · Cited by 200
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
Zhu, X., Fujita, M., Snyder, L. A., & Okada, H. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0473-5 · Cited by 189
Macrophage-Induced Tumor Angiogenesis Is Regulated by the TSC2–mTOR Pathway
Chen, W., Ma, T., Shen, X.-N., Xia, X.-F., Xu, G.-D., Bai, X.-L., & Liang, T.-B. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2684 · Cited by 189
Roland, C. L., Dineen, S. P., Lynn, K. D., Sullivan, L. A., Dellinger, M. T., Sadegh, L., Sullivan, J. P., Shames, D. S., & Brekken, R. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0280 · Cited by 188
Meng, Y., Beckett, M. A., Liang, H., Mauceri, H. J., van Rooijen, N., Cohen, K. S., & Weichselbaum, R. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2995 · Cited by 181
Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy
Huang, Z., Zhang, Z., Jiang, Y., Zhang, D., Chen, J., Dong, L., & Zhang, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.013 · Cited by 169
Eubank, T. D., Roberts, R. D., Khan, M., Curry, J. M., Nuovo, G. J., Kuppusamy, P., & Marsh, C. B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1405 · Cited by 166
NF-κB as a central regulator of macrophage function in tumors
Biswas, S. K., & Lewis, C. E. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0310153 · Cited by 161
Fujiwara, Y., Komohara, Y., Ikeda, T., & Takeya, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01772.x · Cited by 154
Dai, F., Liu, L., Che, G., Yu, N., Pu, Q., Zhang, S., Ma, J., Ma, L., & You, Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-220 · Cited by 153
Jin, G., Kawsar, H. I., Hirsch, S. A., Zeng, C., Jia, X., Feng, Z., Ghosh, S. K., Zheng, Q. Y., Zhou, A., McIntyre, T. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010993 · Cited by 153
Nuclear Factor-κB and Tumor-Associated Macrophages
Mancino, A., & Lawrence, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1015 · Cited by 152
TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth
Standiford, T. J., Kuick, R., Bhan, U., Chen, J., Newstead, M., & Keshamouni, V. G. (2011) · Oncogene · doi:10.1038/onc.2010.619 · Cited by 151
Jassar, A. S., Suzuki, E., Kapoor, V., Sun, J., Silverberg, M. B., Cheung, L., Burdick, M. D., Strieter, R. M., Ching, L., Kaiser, L. R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1658 · Cited by 148
Buhtoiarov, I. N., Sondel, P. M., Wigginton, J. M., Buhtoiarova, T. N., Yanke, E. M., Mahvi, D. A., & Rakhmilevich, A. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03357.x · Cited by 143
Chen, G. T. Y., Chiang, C., Wang, C., Tsai, C.-S., Jung, S., Lee, C.-C., McBride, W. H., & Hong, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1471 · Cited by 141
89 Zr-Labeled Dextran Nanoparticles Allow in Vivo Macrophage Imaging
Keliher, E. J., Yoo, J., Nahrendorf, M., Lewis, J. S., Marinelli, B. S., Newton, A., Pittet, M. J., & Weissleder, R. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200405d · Cited by 138
Hiraoka, K., Zenmyo, M., Watari, K., Iguchi, H., Fotovati, A., Kimura, Y. N., Hosoi, F., Shoda, T., Nagata, K., Osada, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00880.x · Cited by 135
Nagai, T., Tanaka, M., Tsuneyoshi, Y., Xu, B., Michie, S. A., Hasui, K., Hirano, H., Arita, K., & Matsuyama, T. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0667-x · Cited by 134
Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans
Metelitsa, L. S. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.10.005 · Cited by 134
Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3
Chang, Y., Chen, T., Lee, C., Yang, C.-Y., Wang, H., Wang, C.-C., & Hsieh, S.-L. E. (2008) · Blood · doi:10.1182/blood-2007-12-130609 · Cited by 132
Buhtoiarov, I. N., Lum, H. D., Berke, G., Paulnock, D. M., Sondel, P. M., & Rakhmilevich, A. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6013 · Cited by 129
An Ets2 -Driven Transcriptional Program in Tumor-Associated Macrophages Promotes Tumor Metastasis
Zabuawala, T., Taffany, D. A., Sharma, S. M., Merchant, A. S., Adair, B., Srinivasan, R., Rosol, T. J., Fernández, S., Huang, K., Leone, G. W., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1474 · Cited by 127
Pyonteck, S. M., Gadea, B. B., Wang, H.-W., Gocheva, V., Hunter, K. E., Tang, L. H., & Joyce, J. A. (2011) · Oncogene · doi:10.1038/onc.2011.337 · Cited by 126
Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma
Song, L., Ara, T., Wu, H., Woo, C., Reynolds, C. P., Seeger, R. C., DeClerck, Y. A., Thiele, C. J., Sposto, R., & Metelitsa, L. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30751 · Cited by 123
Tyagi, A., Singh, R. P., Ramasamy, K., Raina, K., Redente, E. F., Dwyer‐Nield, L. D., Radcliffe, R. A., Malkinson, A. M., & Agarwal, R. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0095 · Cited by 120
Alternative activation of macrophages by IL‐4 requires SHIP degradation
Weisser, S. B., McLarren, K. W., Voglmaier, N., van Netten‐Thomas, C. J., Antov, A., Flavell, R. A., & Sly, L. M. (2011) · European Journal of Immunology · doi:10.1002/eji.201041105 · Cited by 118
Role of tumour-associated macrophages in cancer-related inflammation.
Sica, A. (2010) · PubMed · Cited by 117
Manthey, C. L., Johnson, D. L., Illig, C. R., Tuman, R. W., Zhao, Z., Baker, J. F., Chaikin, M. A., Donatelli, R. R., Franks, C. F., Zeng, L., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0255 · Cited by 115
Leimgruber, A., Berger, C., Cortez‐Retamozo, V., Etzrodt, M., Newton, A., Waterman, P. R., de Figueiredo, J. L., Köhler, R. H., Elpek, N. M., Mempel, T. R., et al. (2009) · Neoplasia · doi:10.1593/neo.09356 · Cited by 113
Miselis, N. R., Wu, Z. J., van Rooijen, N., & Kane, A. B. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0579 · Cited by 113
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
Veltman, J. D., Lambers, M. E. H., van Nimwegen, M., Hendriks, R. W., Hoogsteden, H. C., Hegmans, J. P., & Aerts, J. G. J. V. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605814 · Cited by 111
Komohara, Y. (2011) · Oncology Reports · doi:10.3892/or.2011.1454 · Cited by 108
Kurahara, H., Takao, S., Kuwahata, T., Nagai, T., Ding, Q., Maeda, K., Shinchi, H., Mataki, Y., Maemura, K., Matsuyama, T., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2263-0 · Cited by 104
Lewén, S., Zhou, H., Hu, H., Cheng, T., Markowitz, D., Reisfeld, R. A., Xiang, R., & Luo, Y. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0389-x · Cited by 101
Álvaro, T., Lejeune, M., Camacho, F. I., Salvadó, M. T., Sánchez, L., García, J. F., López, C., Jaén, J., Bosch, R., Pons, L. E., et al. (2006) · PubMed · Cited by 93
Edwards, J. P., & Emens, L. A. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.07.002 · Cited by 91
Zent, C. S., Smith, B. J., Ballas, Z. K., Wooldridge, J. E., Link, B. K., Call, T. G., Shanafelt, T. D., Bowen, D. A., Kay, N. E., Witzig, T. E., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.608451 · Cited by 90
Scavenger Receptor-A–Targeted Leukocyte Depletion Inhibits Peritoneal Ovarian Tumor Progression
Bąk, S., Walters, J. J., Takeya, M., Conejo-Garcia, J. R., & Berwin, B. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4410 · Cited by 89
Buhtoiarov, I. N., Lum, H. D., Berke, G., Sondel, P. M., & Rakhmilevich, A. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.309 · Cited by 88
Mankan, A., & Greten, F. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601739 · Cited by 83
Chan, L. L. Y., Cheung, B. K. W., Li, J., & Lau, A. S. Y. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1009659 · Cited by 78
Weber, J. S., Zarour, H. M., Redman, B. G., Trefzer, U., O'Day, S. J., van den Eertwegh, A. J. M., Marshall, M. E., & Wagner, S. N. (2009) · Cancer · doi:10.1002/cncr.24473 · Cited by 77
Immune Mechanisms and Therapeutic Potential of CpG Oligodeoxynucleotides
Wilson, H. L., Dar, A. M., Napper, S., Lopez, A. M., Babiuk, L. A., & Mutwiri, G. (2006) · International Reviews of Immunology · doi:10.1080/08830180600785868 · Cited by 76
Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages
Tsagozis, P., Eriksson, F., & Pisa, P. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0482-9 · Cited by 75
Clinical and Biological Implications of the Tumor Microenvironment
Jackson, D. G. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0099-6 · Cited by 74
Vishvakarma, N. K., & Singh, S. M. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.09.002 · Cited by 73
Chang, C.-J., Chen, Y.-H., Huang, K., Cheng, H.-W., Chan, S.-F., Tai, K., & Hwang, L. (2007) · Hepatology · doi:10.1002/hep.21560 · Cited by 69
Galmbacher, K., Heisig, M., Hotz, C., Wischhusen, J., Galmiche, A., Bergmann, B., Gentschev, I., Goebel, W., Rapp, U. R., & Fensterle, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009572 · Cited by 65
Pulaski, H. L., Spahlinger, G., Silva, I. A., McLean, K., Kueck, A. S., Reynolds, R. K., Coukos, G., Conejo-Garcia, J. R., & Buckanovich, R. J. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-49 · Cited by 62
Zoledronic acid use in cancer patients: More than just supportive care?
Coleman, R. E., Cook, R. J., Hirsh, V., Major, P. P., & Lipton, A. (2010) · Cancer · doi:10.1002/cncr.25529 · Cited by 61
Macrophages, PPARs, and Cancer
Ginderachter, J. A. V., Movahedi, K., den Bossche, J. V., & BAETSELIER, P. D. (2008) · PPAR Research · doi:10.1155/2008/169414 · Cited by 61
Liang, W. P., Kujawski, M., Wu, J., Lu, J., Herrmann, A., Loera, S., Yen, Y., Lee, F., Yu, H., Wen, W. X., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1486 · Cited by 61
Melancon, M. P., Lü, W., Huang, Q., Thapa, P., Zhou, D., Ng, C. S., & Li, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.001 · Cited by 53
Decoy Receptor 3 Enhances Tumor Progression via Induction of Tumor-Associated Macrophages
Tai, S., Chang, H.-C., Lan, K.-L., Lee, C.-T., Yang, C.-Y., Chen, N., Chou, T., Tarng, D., & Hsieh, S.-L. E. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101101 · Cited by 46
Smith, K., Hamza, S. H., & Skelton, H. G. (2004) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2004.01593.x · Cited by 45
Tugues, S., Honjo, S., König, C. M., Noguer, O., Hedlund, M., Botling, J., Deschoemaeker, S., Wenes, M., Rolny, C., Jahnen‐Dechent, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2194 · Cited by 43
Tumor-Associated Macrophages as Targets for Tumor Immunotherapy
Weigert, A., Sekar, D., & Brüne, B. (2008) · Immunotherapy · doi:10.2217/1750743x.1.1.83 · Cited by 41
Chauhan, P., Sodhi, A., & Shrivastava, A. (2008) · Immunobiology · doi:10.1016/j.imbio.2008.07.012 · Cited by 41
Chakraborty, P., Chatterjee, S., Ganguly, A., Saha, P., Adhikary, A., Das, T., Chatterjee, M., & Choudhuri, S. K. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0611287 · Cited by 41
Watkins, S. K., Li, B., Richardson, K. S., Head, K. Z., Egilmez, N. K., Zeng, Q., Suttles, J., & Stout, R. D. (2009) · European Journal of Immunology · doi:10.1002/eji.200839010 · Cited by 38
Chen, Q., & Ross, A. C. (2007) · PubMed · Cited by 37
The backbone of progress – preclinical studies and innovations with zoledronic acid
Green, J. R., & Guenther, A. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(11)70003-8 · Cited by 37
STAT3 activation in macrophages following infection with Salmonella
Lin, T., & Bost, K. L. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.039 · Cited by 33
Shrivastava, P., Singh, S. M., & Singh, N. (2004) · Journal of Biomedical Science · doi:10.1007/bf02256128 · Cited by 25
Lo, S. Z. Y., Steer, J. H., & Joyce, D. A. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.020 · Cited by 22
TAMable tumor-associated macrophages in response to innate RNA sensing
Seya, T., Shime, H., & Matsumoto, M. (2012) · OncoImmunology · doi:10.4161/onci.19894 · Cited by 19
Takahashi, T., Ibata, M., Yu, Z., Shikama, Y., Endo, Y., Miyauchi, Y., Nakamura, M., Tashiro‐Yamaji, J., Miura‐Takeda, S., Shimizu, T., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0708-5 · Cited by 17
Gill, J. H., & Roberts, R. A. (2008) · Wiley eBooks · doi:10.1002/9783527610754.md04 · Cited by 2
Cited by
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Chanmee, T., Ontong, P., Konno, K., & Itano, N. (2014) · Cancers · doi:10.3390/cancers6031670 · Cited by 1,538
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
Li, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., Chu, R., Song, H., Xie, D., Jiang, X., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310514 · Cited by 737
Tan, H.-Y., Wang, N., Li, S., Hong, M., Wang, X., & Feng, Y. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2795090 · Cited by 657
Anatomy of a Discovery: M1 and M2 Macrophages
Mills, C. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00212 · Cited by 449
Metadata
- Authors
- Tang, X., Mo, C., Wang, Y., Wei, D., & Xiao, H.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2013-01-16
- Volume
- 138
- Issue
- 2
- Pages
- 93-104
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W2019179700
- Cited by
- 278
- References
- 154
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.